April 28, 2026 • Vol. 1, Issue 6
Contact & Correspondence
We welcome inquiries, tips, letters to the editor, and article ideas from the MBS community. Reach us at [email protected] — your submissions help shape what we cover. | Coming Soon
Invited surgeon commentaries are forthcoming. If you are interested in contributing a perspective or editorial on a topic relevant to metabolic and bariatric surgery, please contact us at [email protected]. |
Henry B. Gonzalez Convention Center, San Antonio, Texas. Up to 63 AMA PRA Category 1 CME credits available. Full exhibit hall, hands-on sessions, and networking along the Riverwalk.
Register or manage your registration at asmbs.org.
Angle of His Accentuation Cuts Post-Sleeve GERD to Near ZeroAhmad S et al. — Obes Surg. Published online April 25, 2026
A retrospective cohort of 192 laparoscopic sleeve gastrectomy patients in Jordan compared standard LSG against LSG with Angle of His accentuation. Twelve-month GERD rates were 38.2% in the standard group versus 2.9% in the accentuation group (p<0.001), while weight loss was identical at every measurement point. The technique involves placing the final staple 1–2 cm lateral to the native angle and anchoring the fundic remnant to the left diaphragmatic crus. In the hiatal hernia subgroup, zero patients in the accentuation arm developed reflux versus 38.5% in the standard arm — though the small n makes that result exploratory. Non-randomized design warrants prospective confirmation, but the signal is substantial enough to merit attention at any program performing high-volume sleeve work. > Obes Surg — doi:10.1007/s11695-026-08703-4Technical Note
GERD at 12 months: 38.2% standard LSG vs. 2.9% with Angle of His accentuation (p<0.001). Weight loss identical across both groups. HH subgroup: 0% vs. 38.5% (exploratory). Zero leaks in the accentuation arm. The 1–2 cm lateral staple placement + fundic crus anchoring is the operative variable. | Time-Restricted Eating Offers No Weight Advantage Post-Sleeve — and May Cause HarmGhoreishy SM et al. — Obes Surg. Published online April 28, 2026
A 12-week RCT enrolled 48 patients with weight regain of ≥10% at least two years after sleeve gastrectomy, randomized to time-restricted eating plus calorie restriction (8-hour window, 1,000–1,200 kcal/day) or calorie restriction alone. No statistically significant between-group difference in weight loss or body composition emerged. The TRE group showed significant lean body mass loss (p=0.01), reduced basal metabolic rate (p=0.003), and worsened fasting glucose (p<0.001) — all in the wrong direction. The calorie restriction-only group improved food addiction symptoms (p=0.02) and neuroticism scores. The authors recommend prioritizing protein distribution across meals rather than temporal restriction when addressing post-bariatric weight regain. > Obes Surg — doi:10.1007/s11695-026-08707-0Clinical Alert
TRE group adverse signals: lean mass loss (p=0.01), ↓BMR (p=0.003), ↑fasting glucose (p<0.001). CR-only: improved food addiction (p=0.02) and neuroticism. Time restriction confers no weight benefit post-sleeve and produces metabolic signals in the wrong direction. Protein distribution across meals is the preferred strategy. | |
Bariatric Surgery Produces Clinically Meaningful Migraine ReliefAli M et al. — BMJ Neurol Open. 2026
A prospective cohort of 48 migraine patients undergoing bariatric surgery in Egypt tracked headache burden at 12 months. Monthly migraine days dropped by a median of 4 days, HIT-6 scores fell 6 points (exceeding the clinically meaningful threshold), and VAS pain scores decreased by 2 points — all with p<0.001. Prophylactic medication use fell from 56.3% to 29.2% of patients. Each 1-unit BMI reduction was associated with a 23.1% greater odds of achieving meaningful improvement. The study is small and relies on self-reported outcomes, but the effect size is large. For patients with comorbid migraine, this adds a substantive data point to the pre-op counseling conversation. > BMJ Neurol Open — doi:10.1136/bmjno-2025-001388Comorbidity Benefit
Migraine days: −4/month (p<0.001). HIT-6: −6 points, exceeding clinical threshold (p<0.001). VAS pain: −2 points. Prophylactic medication use: 56.3% → 29.2%. Per 1-unit BMI reduction: 23.1% greater odds of clinically meaningful headache improvement. | MBSC Survey: Same-Day Discharge After Bariatric Surgery Has Almost No AdvocatesChoo K et al. — Surg Obes Relat Dis. Accepted March 27, 2026
A 100% response rate survey of 76 Michigan Bariatric Surgery Collaborative surgeons (May 2024) found that only 20% currently perform same-day discharge after bariatric procedures. Among those who do not, 91% cited failure to rescue as a primary concern and 84% flagged inability to adequately monitor patients. In an unusual result, zero free-text responses endorsed SDD for any reason. Barriers most frequently cited were safety concerns (54%) and lack of outpatient support resources (29%). As payers continue to push for cost-reduction through shortened stays, this survey provides a useful counterpoint: the surgeons closest to the outcomes are not convinced. > Surg Obes Relat Dis — doi:10.1016/j.soard.2026.03.035Surgeon Survey
76 MBSC surgeons, 100% response rate. Only 20% perform SDD. Non-SDD concerns: failure to rescue (91%), inadequate monitoring (84%). Barriers: safety (54%), outpatient support gaps (29%). Zero free-text responses endorsed same-day discharge for any indication. | |
OCULUS Trial: Clear Liquid Diet Eliminates GLP-1 Aspiration Risk Regardless of Medication HoldingAhmad AI et al. — JAMA Intern Med. Published March 16, 2026
The OCULUS trial randomized 60 adults at two Cleveland Clinic centers to assess residual gastric volume (RGV) risk in GLP-1/GIP users undergoing upper endoscopy. Continuing GLP-1 medications significantly increased clinically relevant RGV. Holding one dose reduced risk. The pivotal clinical finding: a clear liquid diet the day before the procedure eliminated clinically relevant RGV regardless of whether the medication was held or continued. No aspiration events occurred in either group. OCULUS-2, examining bowel prep quality in GLP-1 users, is currently underway. > JAMA Intern Med — doi:10.1001/jamainternmed.2026.0027Practical Takeaway
Clear liquid diet the prior day eliminates clinically relevant RGV from GLP-1 medications — even without medication discontinuation. Holding one dose also reduces risk. For patients on GLP-1s requiring upper endoscopy, dietary prep may be the more actionable and reliable intervention. OCULUS-2 (bowel prep) underway. | ||
SYNCHRONIZE-1: Survodutide Delivers 16.6% Weight Loss vs. 3.2% Placebo Over 76 WeeksBoehringer Ingelheim / Zealand Pharma — Phase III Press Release, April 28, 2026
Boehringer Ingelheim and Zealand Pharma announced Phase III results from SYNCHRONIZE-1, evaluating survodutide — a dual glucagon/GLP-1 receptor agonist — in adults with obesity or overweight without type 2 diabetes. At 76 weeks, participants lost an average of 16.6% of body weight (approximately 39.2 lbs / 17.8 kg) versus 3.2% placebo (p<0.001); more than 85% achieved at least 5% weight loss. Weight loss was predominantly fat-driven with minimal lean mass impact. Full data will be presented at ADA 2026 in June. Survodutide is also in Phase III LIVERAGE and LIVERAGE-Cirrhosis trials for MASH. Context: tirzepatide achieved approximately 20.9% and semaglutide approximately 14.9% in their respective Phase III obesity trials — survodutide sits between the two, though cross-trial comparisons are inherently limited. The drug remains investigational; no FDA approval timeline has been announced. > Boehringer Ingelheim Press Release — SYNCHRONIZE-1 Phase III, April 28, 2026Pipeline Context
Survodutide: −16.6% body weight (−39.2 lbs) at 76 weeks; 85.1% achieved ≥5% loss. Benchmark: tirzepatide ~20.9%, semaglutide ~14.9%. Investigational; full data at ADA June 2026. Additional Phase III trials for MASH (LIVERAGE, LIVERAGE-Cirrhosis) ongoing. No FDA approval timeline announced. | Foundayo Launches Slowly While Oral Wegovy Sprints: The First Two Weeks of the Oral GLP-1 WarReuters / IQVIA Prescription Data — April 24, 2026
Eli Lilly’s Foundayo (orforglipron), the first non-peptide small-molecule oral GLP-1 receptor agonist for chronic weight management, received FDA approval April 1, 2026. Two-week prescription data: Foundayo generated 1,390 prescriptions in Week 1 and 3,707 in Week 2; oral semaglutide (Novo Nordisk’s oral Wegovy) posted 3,071 in its own first days and 18,410 in Week 2. Lilly stock fell approximately 4% on the disclosure; 2026 revenue forecasts were cut from ~$4 billion to $1.3–1.6 billion, though peak sales estimates (~$30 billion) remain intact. Practical differences for patient counseling: Foundayo has no food or water restrictions, any-time-of-day dosing ($149/month self-pay; $25/month commercial; Medicare Part D expected ~July 2026 at ~$50/month). Oral Wegovy requires empty stomach and 30-minute fast. Foundayo’s label includes drug interactions with simvastatin and oral contraceptives. Novo disputes Lilly’s cross-trial claim of ~3% greater weight loss for oral semaglutide; no head-to-head trial has been completed. > Reuters / IQVIA — April 24, 2026Launch Metrics
Foundayo Wk 1: 1,390 Rx • Wk 2: 3,707 Rx. Oral Wegovy Wk 2: 18,410 Rx. LLY −4% on data release. 2026 Foundayo revenue est. cut to $1.3–1.6B (from ~$4B). Dosing advantage: Foundayo anytime, no food restrictions; oral Wegovy empty stomach + 30-min fast. Drug interactions: simvastatin, oral contraceptives. |
GLP-1 Receptor Agonists Work in IBD Patients, and They Don’t Appear to Worsen DiseaseJan A, Dubwa D — Obes Pillars. Accepted April 26, 2026
Roughly 15–40% of patients with inflammatory bowel disease carry a diagnosis of obesity, a combination that complicates both conditions. A systematic review in Obesity Pillars addresses whether GLP-1 receptor agonists are a viable weight management option in this group. Across 7 studies (n=16 to 47,424; follow-up 3–18 months), GLP-1 RAs produced consistent weight loss: median 6.2 kg in the smallest study to mean 9.5 kg in longer-duration work. Tirzepatide and semaglutide outperformed liraglutide. Heavier patients and longer treatment duration produced greater loss. GI side effects were common but generally mild with dose titration. Crucially, none of the included studies found a significant increase in IBD exacerbations or disease worsening. The evidence base is entirely retrospective and largely US-based; RCTs are needed before formal practice guidance can be issued. > Obes Pillars — doi:10.1016/j.obpill.2026.100272IBD-Obesity Overlap
7 studies; n=16 to 47,424; 3–18 months follow-up. Weight loss: 6.2–9.5 kg. Tirzepatide/semaglutide outperformed liraglutide. No IBD exacerbations found across any included study. All evidence retrospective; RCTs required. A reasonable foundation for informed patient discussion in the obesity-IBD overlap. | MBS Improves More Than Weight: A Framework for Physical, Mental, and Psychosocial OutcomesBoppre G et al. — Int J Obes. Published March 27, 2026
A perspective from an international team (Portugal, Spain, Austria) maps the full scope of what metabolic and bariatric surgery produces over time. Beyond weight loss: improved self-esteem, body image, sexual health, social engagement, and fertility normalization through sex hormone restoration. Systematic reviews document reduced depressive symptoms and anxiety in patients with prior mental health conditions. The mental health picture is not uniformly positive — some patients continue to struggle with body image dissatisfaction after major weight loss, and the literature documents elevated risk of self-harm and suicide compared to BMI-matched controls. Exercise RCTs by this group showed supervised training post-MBS preserved lean mass, enhanced fat loss, and significantly increased muscle strength beyond what surgery produced alone — supporting integration of exercise professionals into standard post-bariatric care teams. > Int J Obes — doi:10.1038/s41366-026-02055-wPsychosocial Lens
Benefits beyond weight: self-esteem, body image, sexual health, fertility. Risk: elevated self-harm/suicide vs. BMI-matched controls post-major weight loss. Exercise RCTs: supervised training adds lean mass preservation and muscle strength gains beyond surgery alone. Psychological follow-up should be ongoing — not a pre-op checkbox. | |
GLP-1 Medicines Do Not Cause Disproportionate Muscle Loss in Obese Mice or HumansLanger HT et al. — Cell Rep Med. Published March 17, 2026
This multi-institutional study (Charité Berlin, UC Davis, University of Nottingham) is the most comprehensive pre-clinical and clinical examination of the GLP-1 muscle-loss question to date. Four pre-clinical studies in diet-induced obese mice used semaglutide, tirzepatide, and survodutide; a proof-of-concept clinical trial enrolled 10 patients with obesity and type 2 diabetes treated with semaglutide for 12 weeks (NCT05606471). GLP-1 medicines do cause a small absolute decrease in muscle mass, but the loss is not disproportionate and does not impair function — grip strength and maximum voluntary knee extension were both unchanged in humans. A key methodological note: DXA cannot distinguish intra-hepatic triglyceride reduction from muscle loss. Liver mass decreased 20–55% in pre-clinical groups, likely inflating prior estimates of muscle wasting. Proteomics show GLP-1RA upregulates mitochondrial proteins in muscle versus calorie restriction alone — suggesting a distinct and potentially favorable molecular effect on muscle biology. > Cell Rep Med — doi:10.1016/j.xcrm.2026.102665Muscle Loss Reframed
Small absolute muscle mass decrease with GLP-1 RAs — not disproportionate, not functionally impairing. Grip strength and MVC unchanged in humans. DXA confound: liver mass (not muscle) accounts for much of prior “lean mass loss.” Mitochondrial protein upregulation in muscle suggests a favorable effect vs. calorie restriction alone. | ||
Novo Nordisk Bets on AI — But Is the OpenAI Partnership a Real Game Changer?Motley Fool / Yahoo Finance — April 27, 2026
Novo Nordisk entered a partnership with OpenAI on April 14, 2026, making it one of the first major pharmaceutical companies to formally enlist the ChatGPT maker for drug discovery, development, and manufacturing operations. CEO Mike Doustdar singled out diabetes and obesity as priority areas. The analysis is measured: even modest reductions in development cost or timeline translate to meaningful downstream impact, but AI in drug discovery operates on timelines measured in years, not quarters. Eli Lilly has already built the largest AI supercomputer in pharma and is further along in integration — Novo is playing catch-up in this dimension. Separately, Novo entered a $2.1 billion partnership with Vivtex Corporation to develop next-generation oral biologic medicines for obesity and diabetes — potentially enabling peptide-based drugs delivered orally without historical absorption barriers. The Vivtex deal may ultimately prove more consequential for the pipeline. Both are long-duration bets for a company facing a projected 5–13% revenue decline in 2026. > Motley Fool / Yahoo Finance — April 27, 2026Strategic Watch
NVO-OpenAI: diabetes and obesity as priority areas; AI for discovery, development, and manufacturing. Lilly’s AI infrastructure more advanced. Vivtex deal ($2.1B): oral biologic obesity/diabetes pipeline — potentially more consequential than OpenAI agreement for near-term differentiation. Both are multi-year bets against a projected 5–13% 2026 revenue headwind. | Pfizer’s Once-Monthly Oral GLP-1 Candidate Posts Positive Phase 2b DataSimply Wall St / TipRanks — April 24, 2026
While market attention has been fixed on the Lilly-Novo duopoly, Pfizer reported positive Phase 2b results for PF-08653944, its investigational once-monthly oral GLP-1 receptor agonist for obesity. Pfizer is not a near-term competitive threat — Phase 3 confirmation is required, and commercial launch would be several years away assuming positive results. What matters is the differentiation: both Foundayo and oral semaglutide require daily dosing. A monthly oral option, if Phase 3-confirmed, would address the single biggest adherence challenge in GLP-1 therapy. Real-world persistence data on injectable GLP-1s shows more than half of patients discontinue within the first year; daily oral regimens face similar pressures. For the MBS community, the relevant question is what the pharmacotherapy landscape looks like in 3–4 years for patients who might otherwise be referred for surgery or who regain weight post-procedure. > Simply Wall St / TipRanks — April 24, 2026Pipeline Watch
PF-08653944: Phase 2b positive. Once-monthly oral vs. daily for Foundayo and oral Wegovy. Phase 3 required; commercial launch minimum 3–4 years. If confirmed: directly targets the largest adherence gap in GLP-1 therapy, where >50% of patients discontinue injectable therapy within 12 months. |
Prices as of market close / intraday April 28, 2026 · Sources: Investing.com, Robinhood, Macrotrends, StockAnalysis, Google Finance
| Ticker | Company | Price | 52-Wk Range | Key Context |
|---|---|---|---|---|
| ISRG | Intuitive Surgical | $482 | $428–$604 | YTD −14.9%; Q1 beat expectations; tariff/macro headwinds; market cap ~$171B |
| MDT | Medtronic | $86 | $74–$106 | YTD −15%; $185M FY26 tariff impact; Q3 revenue $8.6B (+8.4%); raised FY EPS guidance $5.60–$5.66 |
| BSX | Boston Scientific | $61 | $45–$82 | Q1 9.4% organic growth; FY guidance lowered (EP/WATCHMAN/urology); securities class action May 4 deadline |
| TFX Reports 4/30 | Teleflex | $132 | $100–$139 | Near 52-wk high; Strong Buy technical signals; analyst consensus target ~$133 |
| LLY Reports 4/30 | Eli Lilly | $871 | $624–$1,134 | Foundayo Wk 1–2 Rx lagged oral Wegovy; stock −4% on data; $2.3B Ajax acquisition; MariTide data at ADA June |
| NVO Reports 5/6 | Novo Nordisk | $41 | $35–$81 | −5% to −13% 2026 sales guidance; oral Wegovy outpacing Foundayo; OpenAI + Vivtex deals; active buyback |
| AMLX | Amylyx Pharma | $17 | $10–$24 | Strong Buy (9 analysts); avg target $24.80; avexitide Phase 3 for post-bariatric hypoglycemia; WAC $183,333/pt |
| PFE Reports 5/5 | Pfizer | $27 | $22–$29 | Near 52-wk high; Phase 2b positive for monthly oral GLP-1 (PF-08653944); GS Hold / target $26 |
| ABT | Abbott | $93 | $91–$139 | Near 52-wk low; multiple analyst target cuts post-Q1; Exact Sciences integration costs; positive PFA data at HRS 2026 |
| AMGN Reports 4/30 | Amgen | $348 | $261–$391 | Hold consensus; MariTide monthly-to-quarterly obesity dosing as key differentiator; 2026 revenue guidance $37–38.4B |
| VTRS Reports 5/7 | Viatris | $15 | $8–$15 | Up ~94% over past year; near 52-wk high; Q1 EPS est. $0.52 (+4% YoY); biosimilar/generic pipeline traction |
The MBS Digest is not affiliated wth any medical society or medical industry. Information provided for educational purposes only. Prices as of market close / intraday April 28, 2026. Finance Tracker is for informational purposes only and does not constitute investment advice. MBS Digest and its editorial board hold no positions in any companies covered. Sources: Investing.com, Robinhood, Macrotrends, StockAnalysis, Google Finance. © 2026 MBS Digest. Trademark pending, USPTO